Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFT8634 in Advanced SMARCB1-Perturbed Cancers
NCT05355753Phase 1Terminated
- Sponsor
- C4 Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of sendegobresib in synovial sarcoma (SS) and malignant rhabdoid tumor (MRT) (4 arms), sponsored by C4 Therapeutics. Primary endpoints: Adverse Events, Safety Laboratory Changes and 3 more. Started Mar 2022; status: terminated.
02
Drugs
sendegobresib
03
Conditions
synovial sarcoma (SS)malignant rhabdoid tumor (MRT)
Beyond the preview
Go deeper on NCT05355753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355753.